Cargando…

A Comparison of the Clinical and Radiological Extent of Denosumab (Xgeva(®)) Related Osteonecrosis of the Jaw: A Retrospective Study

Medication-related osteonecrosis of the jaw (MRONJ) is a severe side effect of antiresorptive medication. The aim of this study was to evaluate the incidence of denosumab-related osteonecrosis of the jaw and to compare the clinical and radiological extent of osteonecrosis. A retrospective study of p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Assili, Zineb, Dolivet, Gilles, Salleron, Julia, Griffaton-Tallandier, Claire, Egloff-Juras, Claire, Phulpin, Bérengère
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197814/ https://www.ncbi.nlm.nih.gov/pubmed/34071481 http://dx.doi.org/10.3390/jcm10112390

Ejemplares similares

Denosumab and osteonecrosis of the jaw
por: Bower, Robert
Publicado: (2019)

Osteonecrosis of the jaw and denosumab
por: Goss, Alastair N
Publicado: (2022)

Bone Metastases Treatment by Sm-153 Oxabifore in Combination with Monoclonal Antibody Denosumab (Xgeva)
por: Joob, Beuy, et al.
Publicado: (2014)

Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval
por: Cadieux, Benoit, et al.
Publicado: (2022)

Plasmablastic lymphoma: oral presentation in patient suffering from osteradionecrosis of the jaw
por: Kichenbrand, C., et al.
Publicado: (2016)

Denosumab Related Osteonecrosis of Jaw: a Case Report
por: de Sales Lima, Marco Vinícius, et al.
Publicado: (2018)

Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab
por: Neuprez, A., et al.
Publicado: (2013)

Osteonecrosis of the Jaw
por: Lončar Brzak, Božana, et al.
Publicado: (2023)

NIR fluorescence-guided tumor surgery: new strategies for the use of indocyanine green
por: Egloff-Juras, Claire, et al.
Publicado: (2019)

Effectiveness of Bone Metastases Treatment by Sm-153 Oxabifore in Combination with Monoclonal Antibody Denosumab (Xgeva): First Experience
por: Rasulova, Nigora, et al.
Publicado: (2013)

A randomized trial comparing LY01011, biosimilar candidate, with the reference product denosumab (Xgeva®) in healthy Chinese subjects
por: Ding, Yanhua, et al.
Publicado: (2023)

384. Denosumab-Related Osteonecrosis of the Jaw: an Emergent and Potentially Complex Bone and Joint Infection
por: Bricca, Romain, et al.
Publicado: (2019)

Denosumab/ibandronic acid/zoledronic acid: Medication-related osteonecrosis of jaw: case report
Publicado: (2021)

Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab
por: Wick, Alexander, et al.
Publicado: (2021)

Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw
por: Fu, Pei-An, et al.
Publicado: (2023)

Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review
por: de Oliveira, Camila-Carvalho, et al.
Publicado: (2016)

Osteonecrosis of the jaws associated with denosumab: Study of clinical and radiographic characteristics in a series of clinical cases
por: Tofé, Victoria I., et al.
Publicado: (2020)

Validation of a Three-Dimensional Head and Neck Spheroid Model to Evaluate Cameras for NIR Fluorescence-Guided Cancer Surgery
por: Egloff-Juras, Claire, et al.
Publicado: (2021)

Denosumab Related Osteonecrosis of the Jaw with Spontaneous Necrosis of the Soft Palate: Report of a Life Threatening Case
por: Qaisi, Mohammed, et al.
Publicado: (2016)

A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients
por: Jung, Seoyeon, et al.
Publicado: (2022)

Long-Term Alterations of Cytokines and Growth Factors Expression in Irradiated Tissues and Relation with Histological Severity Scoring
por: Gallet, Patrice, et al.
Publicado: (2011)

Denosumab-related osteonecrosis of the jaw in a patient with bone metastases of prostate cancer: A case report and literature review
por: Yoshimura, Hitoshi, et al.
Publicado: (2017)

Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers
por: Okuma, Satoe, et al.
Publicado: (2020)

Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review
por: Raimondi, Alessandra, et al.
Publicado: (2020)

Feasibility of Treating Irradiated Bone with Intramedullary Delivered Autologous Mesenchymal Stem Cells
por: Phulpin, Bérengère, et al.
Publicado: (2011)

Bisphophonates related osteonecrosis of the jaw
por: Gupta, Swati, et al.
Publicado: (2013)

Medication-Related Osteonecrosis of the Jaws: Considerations on a New Antiresorptive Therapy (Denosumab) and Treatment Outcome after a 13-Year Experience
por: Favia, Gianfranco, et al.
Publicado: (2016)

Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology
por: Fusco, Vittorio, et al.
Publicado: (2018)

Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis
por: Limones, Alvaro, et al.
Publicado: (2020)

Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score–matched analysis
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan
por: Liu, Fang-Chun, et al.
Publicado: (2023)

A real‐world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab
por: Bracchi, Paola, et al.
Publicado: (2023)

Bisphosphonate-Related Osteonecrosis of the Jaw Bone: Radiological Pattern and the Potential Role of CBCT in Early Diagnosis
por: Olutayo, James, et al.
Publicado: (2010)

Osteonecrosis of jaw associated with bisphosphonate use
por: Rastogi, Ashu, et al.
Publicado: (2012)

Bisphosphonate-related osteonecrosis of the jaws (Bronj)
por: Beninati, Francesco, et al.
Publicado: (2013)

Osteonecrosis of the jaws in patients treated with bisphosphonates
por: Ata-Ali, Fadi, et al.
Publicado: (2012)

Bisphosphonate-Related Osteonecrosis of the Jaw: Specificities
por: Paulo, Siri, et al.
Publicado: (2014)

Expert opinion about osteonecrosis of the jaw
por: Lee, Jeong Keun
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_j2f1bsj6877sib851iuht28bjb